Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial... HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs. Show more
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application...
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to...
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug...
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer PR...
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
